Spin Master (TOY) appoints Jonathan Roiter to CFO

Spin Master Corp. (TSX: TOY) www.spinmaster.com), a leading global children's entertainment company announced today that Jonathan Roiter will join Spin Master as Executive Vice President & Chief Financial Officer, May 2025. Roiter's appointment follows the previously announced retirement of Mark Segal.

"As we continue to execute against our vision to create magical play experiences for kids and families around the world, we are excited to welcome Jonathan to Spin Master," said Max Rangel, Spin Master's Global President & CEO. "Jonathan brings a wealth of experience in finance operational leadership, M&A and capital markets, which coupled with his deep understanding of the consumer-packaged goods industry will complement our leadership team and strengthen our focus on creating long-term shareholder value. Once again, I want to congratulate Mark on his retirement and thank him for his many contributions during his long tenure as CFO with Spin Master."

Roiter joins Spin Master having most recently served as CFO for Softchoice. A seasoned executive with extensive public company experience, Roiter brings a holistic business focus with a track record of delivering top line and operating margin growth while expanding free cash generation. Prior to Softchoice, he held senior finance roles, including CFO, corporate development, strategy, and operating roles in publicly traded organizations, including GoodFood, Gildan and Ace Bakery, as well as having served as a consultant at McKinsey & Company.

"As a Canadian-founded company, Spin Master has achieved tremendous success on the global stage in its 30-year history," said Roiter. "I look forward to joining the management team to continue to build on the company's legacy by driving growth, fortifying our financial foundation and enhancing shareholder value."

You May Also Be Interested In

• Freedom Broker Starts CarGurus Inc. (CARG) at Buy
• Super Micro Computer offers $3.75 billion in convertible preferred shares
• Cogent Biosciences reports 65% response rate in mastocytosis trial